Effects of HIV Protease Inhibitors on Progression of Monocrotaline- and Hypoxia-Induced Pulmonary Hypertension in Rats
Author(s) -
Guillaume GaryBobo,
Amal Houssaïni,
Valérie Amsellem,
Dominique Rideau,
Pierre Pacaud,
Aline Perrin,
Jérémy Brégeon,
Élisabeth Marcos,
JeanLuc DuboisRandé,
Olivier Sitbon,
Laurent Savale,
Serge Adnot
Publication year - 2010
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.110.973750
Subject(s) - amprenavir , medicine , protein kinase b , pulmonary hypertension , hypoxia (environmental) , pulmonary artery , right ventricular hypertrophy , nitric oxide synthase , pharmacology , gsk 3 , endocrinology , phosphorylation , nitric oxide , biology , biochemistry , protease , chemistry , enzyme , organic chemistry , hiv 1 protease , oxygen
Pulmonary hypertension (PH) is among the complications of HIV infection. Combination antiretroviral therapy may influence the progression of HIV-related PH. Because Akt signaling is a potential molecular target of HIV protease inhibitors (HPIs), we hypothesized that these drugs altered monocrotaline- and hypoxia-induced PH in rats by downregulating the Akt pathway, thereby inhibiting pulmonary artery smooth muscle cell proliferation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom